Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
NCT ID: NCT04331769
Last Updated: 2025-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
400 participants
INTERVENTIONAL
2020-12-21
2030-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiac Resynchronization Therapy (CRT) Efficacy Study
NCT00822146
A Pilot Study of Interventricular Septal Puncture for Cardiac Resynchronization Therapy to Treat Heart Failure
NCT01818765
Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)
NCT00354159
Benefits of µCor in Ambulatory Decompensated Heart Failure
NCT03476187
Contractile Reserve in Dyssynchrony: A Novel Principle to Identify Candidates for Cardiac Resynchronization Therapy
NCT02525185
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects will be randomized in a 1:1 ratio:
1. Treatment group: AccuCinch Ventricular Restoration System plus guideline-directed medical therapy (GDMT) (n\~200)
2. Control group: Guideline-directed medical therapy (GDMT) (n\~200)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Device group: AccuCinch Ventricular Restoration System
Subjects in this arm will receive the AccuCinch Ventricular Restoration System
AccuCinch Ventricular Restoration System
AccuCinch Ventricular Restoration System
Control group: Guideline-Directed Medical Therapy
Subjects in this arm will receive guideline-directed medical therapy (GDMT)
Guideline-Directed Medical Therapy
Guideline-Directed Medical Therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AccuCinch Ventricular Restoration System
AccuCinch Ventricular Restoration System
Guideline-Directed Medical Therapy
Guideline-Directed Medical Therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Ejection Fraction: ≥20% and ≤40% measured by transthoracic echocardiography (TTE) and assessed by an echocardiography (echo) core lab
3. LV end-diastolic diameter ≥55 mm measured by TTE and assessed by an echo core lab
4. Symptom Status:
1. NYHA III,
2. NYHA ambulatory IV, or
3. NYHA II with a heart failure hospitalization within the prior 12 months (of signing the consent)
5. Able to complete six-minute walk test with distance between 100 m and 450 m.
6. Diagnosis and treatment for heart failure should be established at least 90 days before the date of consent. Subjects should be on stable, optimally titrated medical therapy for at least 30 days, as recommended according to current guidelines as standard-of-care for Heart Failure therapy, with any intolerance documented.
1. "Stable" is defined as no more than a 100% increase or a 50% decrease of total daily doses. Medication changes within this range do not require any additional waiting before the screening assessments
2. When a total daily dose increase or decrease exceeds that which is considered stable, the screening TTE and CT will be postponed 30 days after the medication change
3. When additional titration is required to optimize a subject's medication that exceeds what is considered stable, the screening TTE and CT will be postponed at least 30 days after achieving the optimal dose (provided the optimal dose remains outside of the stable parameters)
4. When a dose-for-dose equivalent change in the class of medication change is made, no additional waiting is required before the screening assessments
5. When a change in class medication change exceeds what is considered stable, OR a new class of medication is added, the screening TTE and CT will be postponed 30 days after the medication change
6. If an SGLT2 inhibitor is added to a subject's medications, the screening TTE and CT will be postponed at least 30 days after the addition
7. If an SGLT2 inhibitor dose changes per the stable definition above, no additional waiting is required before the screening assessments
8. If an SGLT2 inhibitor dose change exceeds what is considered stable, the screening TTE and CT will be postponed at least 30 days after achieving the optimal dose (provided the dose remains outside of the stable parameters)
9. When applicable, for guideline-directed device-based therapies: a CRT device must be placed \> 90 days before the screening TTE and CT, and an ICD must be placed \> 30 days before the screening TTE and CT
7. Able and willing to complete all qualifying diagnostic and functional tests, willing to accept blood product transfusion if required and agrees to comply with study follow-up schedule
Exclusion Criteria
1. Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 90 days prior to consent
2. Untreated clinically significant coronary artery disease (CAD) requiring revascularization
3. Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus or vegetation
4. Suboptimal ventricular anatomy or wall thickness as determined from screening echocardiography and/or CT scan
5. Heart failure on the basis other than ischemic or non-ischemic dilated cardiomyopathy (e.g., hypertrophic cardiomyopathy, amyloid cardiomyopathy, restrictive cardiomyopathy, uncorrected congenital heart disease, constrictive pericarditis)
6. Hemodynamic instability within 30 days prior to the implant defined as subject requiring inotropic support or mechanical hemodynamic support
7. Any planned cardiac surgery or interventions within the next 180 days post-randomization (including therapeutic right heart procedures)
8. Active bacterial endocarditis
9. Severe RV dysfunction assessed by right heart catheterization (RHC) and/or TTE
10. Fixed pulmonary hypertension with PA systolic pressure \>70 mmHg not responsive to vasodilator therapy
11. History of any stroke within the prior 90 days of consent or documented Modified Rankin Scale ≥ 2 disability from any prior stroke
Valvular
12. Mitral regurgitation grade 3+ (moderate-severe) or 4+ (severe)
13. Untreated degenerative (primary) mitral valve disease (mild prolapse with no need for intervention is allowable)
14. Prior mitral or aortic valve replacement
15. Tricuspid regurgitation grade 4+ (severe)
16. Moderate or severe aortic valve stenosis (AVA less than 1.5 cm2 or peak velocity AV Vmax \>300 cm/sec)
17. Aortic regurgitation grade 2+ (moderate), 3+ (moderate-severe), or 4+ (severe)
Procedural
18. Anatomical pathology or constraints preventing appropriate access/implant of the AccuCinch Ventricular Restoration System (e.g., femoral arteries will not support a 20F Introducer sheath)
19. Renal insufficiency (i.e., eGFR of \<25 ml/min/1.73 m2)
20. Subjects in whom anticoagulation during the procedure is contraindicated
21. Subjects in whom 90 days of antiplatelet therapy is contraindicated
22. Known allergy to nitinol, polyester, or polyethylene
23. Any prior true anaphylactic reaction to contrast agents; defined as known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to the index procedure
General
24. Life expectancy \<1 year due to non-cardiac conditions
25. Currently participating in another interventional investigational study
26. Subjects on high dose steroids or immunosuppressant therapy
27. Female subjects who are pregnant, of child-bearing potential without a documented birth control method, or who are lactating
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ancora Heart, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin B Leon, MD
Role: STUDY_CHAIR
Columbia University
Ulrich P Jorde, MD
Role: PRINCIPAL_INVESTIGATOR
Montefiore Medical Center/Albert Einstein College of Medicine
Shmuel Chen, MD
Role: PRINCIPAL_INVESTIGATOR
New York Presbyterian/Weill Cornell Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Grandview Medical Group Research, LLC
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Dignity Health St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
Phoenix Cardiovascular Research Group
Phoenix, Arizona, United States
Tucson Medical Center
Tucson, Arizona, United States
Baptist Health Heart Failure & Transplant Institute
Little Rock, Arkansas, United States
University of California San Diego
La Jolla, California, United States
Scripps Health
La Jolla, California, United States
University of Southern California
Los Angeles, California, United States
Kaiser Permanente San Francisco
San Francisco, California, United States
University of California, San Francisco
San Francisco, California, United States
University of Colorado
Aurora, Colorado, United States
Hartford Health
Hartford, Connecticut, United States
Yale University
New Haven, Connecticut, United States
Medstar Health Research Institute
Washington D.C., District of Columbia, United States
JFK Medical Center
Atlantis, Florida, United States
HCA Florida Largo Hospital
Largo, Florida, United States
University of Miami
Miami, Florida, United States
Ascension Sacred Heart
Pensacola, Florida, United States
University of South Florida
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
Piedmont Heart Institute
Atlanta, Georgia, United States
Northside Hospital
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Advocate Good Samaritan Hospital
Downers Grove, Illinois, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Cardiovascular Research Institute of Kansas
Wichita, Kansas, United States
University of Kentucky
Lexington, Kentucky, United States
University of Kentucky
Lexington, Kentucky, United States
Norton Heart Specialists
Louisville, Kentucky, United States
Our Lady of the Lake Regional Medical Center
Baton Rouge, Louisiana, United States
Cardiovascular Institute of the South
Houma, Louisiana, United States
Northern Light Eastern Maine Medical Center
Bangor, Maine, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
University of Massachusetts
Worcester, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Spectrum Health
Grand Rapids, Michigan, United States
William Beaumont Hospital
Royal Oak, Michigan, United States
Ascension Providence Hospital
Southfield, Michigan, United States
Metropolitan Heart and Vascular Institute & Mercy Hosp
Coon Rapids, Minnesota, United States
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States
University of Minnesota
Minneapolis, Minnesota, United States
Jackson Heart Clinic
Jackson, Mississippi, United States
Washington University in St. Louis
St Louis, Missouri, United States
Deborah Heart & Lung
Browns Mills, New Jersey, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Morristown Medical Center
Morristown, New Jersey, United States
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
New Mexico Heart Institute
Albuquerque, New Mexico, United States
University at Buffalo
Buffalo, New York, United States
Northwell Health
Manhasset, New York, United States
NYU Langone Health
New York, New York, United States
Mount Sinai Hospital
New York, New York, United States
CUMC/New York Presbyterian Hospital
New York, New York, United States
Weill Cornell Medicine-New York Presbyterian Hospital
New York, New York, United States
Vassar Brothers Medical Center
Poughkeepsie, New York, United States
St. Francis Hospital
Roslyn, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
NC Heart and Vascular Research, LLC
Raleigh, North Carolina, United States
The Christ Hospital
Cincinnati, Ohio, United States
UH Cleveland Medical Center
Cleveland, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
Ohio State University
Columbus, Ohio, United States
INTEGRIS Baptist Medical Center
Oklahoma City, Oklahoma, United States
Oklahoma Heart Hospital
Oklahoma City, Oklahoma, United States
Oklahoma Heart Institute
Tulsa, Oklahoma, United States
Providence St. Vincent Medical Center
Portland, Oregon, United States
Oregon Health & Science University
Portland, Oregon, United States
Geisinger Clinic
Danville, Pennsylvania, United States
Pinnacle Health Cardiovascular Institute
Harrisburg, Pennsylvania, United States
Penn State Hershey Medical Center
Hershey, Pennsylvania, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
UPMC Heart and Vascular Institute
Pittsburgh, Pennsylvania, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Prisma Health
Columbia, South Carolina, United States
Tennova Healthcare-Turkey Creek Medical Center
Knoxville, Tennessee, United States
Ascension Saint Thomas
Nashville, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Ascension Texas Cardiovascular
Austin, Texas, United States
Austin Heart
Austin, Texas, United States
Baylor Scott & White Research Institute
Dallas, Texas, United States
Houston Heart
Houston, Texas, United States
Baylor College of Medicine St. Luke's Medical Center
Houston, Texas, United States
Houston Methodist Hospital
Houston, Texas, United States
UT Health
Houston, Texas, United States
Texas Tech University Health Sciences Center
Lubbock, Texas, United States
Baylor Scott & White
Plano, Texas, United States
Methodist Healthcare System, San Antonio
San Antonio, Texas, United States
Intermountain Medical Center
Salt Lake City, Utah, United States
University of Virginia Health System
Charlottesville, Virginia, United States
Sentara Norfolk General Hospital
Norfolk, Virginia, United States
CJW Chippenham Medical Center
Richmond, Virginia, United States
Bon Secours St Mary's Hospital
Richmond, Virginia, United States
Carilion Roanoke Memorial Hospital
Roanoke, Virginia, United States
Valley Health Winchester
Winchester, Virginia, United States
University of Washington
Seattle, Washington, United States
Providence Sacred Heart Medical Center
Spokane, Washington, United States
Charleston Area Medical Center
Charleston, West Virginia, United States
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Republican Scientific and Practical Centre of Cardiology
Minsk, , Belarus
OLV Heart Centre
Aalst, , Belgium
AZ Sint-Jan-Oostende AV Campus Brugge
Bruges, , Belgium
St. Anne's University Hospital
Brno, , Czechia
Na Homolce Hospital
Prague, , Czechia
Hôpital de la Timone
Marseille, , France
CHU de Rennes - Hôpital Pontchaillou
Rennes, , France
Clinique-Pasteur
Toulouse, , France
Immanuel Klinikum Bernau Herzzentrum Brandenburg Universitätsklinikum der Medizinischen Hochschule Brandenburg
Bernau, , Germany
Universitätsklinikum Köln (AöR)
Cologne, , Germany
CardioVasculäres Centrum
Frankfurt, , Germany
Universitätsklinikum Halle (Saale)
Halle, , Germany
Universitäres Herz- und Gefäßzentrum Hamburg
Hamburg, , Germany
Hygeia Hospital
Athens, , Greece
Onassis Cardiac Surgery Center
Kallithea, , Greece
Interbalkan Medical Hospital of Thessaloniki
Thessaloniki, , Greece
A O U Policlinico G. Rodolico - San Marco
Catania, Catania, Italy
IRCCS Istituto Clinico Humanitas
Milan, Lombardy, Italy
AOU Città della salute e della Scienza - Ospedale Molinette
Torino, Torino, Italy
Centro Cardiologico Monzino S.p.a
Milan, , Italy
St. Antonius Ziekenhuis
Nieuwegein, , Netherlands
Erasmus Medical Center
Rotterdam, , Netherlands
Institute of Cardiovascular Diseases of Vojvodina
Belgrade, , Serbia
Institute of Cardiovascular Diseases
Belgrade, , Serbia
University Clinical Centre of Serbia
Belgrade, , Serbia
University Clinical Center Niš
Niš, , Serbia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ashley Corlies
Role: primary
Brianna Grimm
Role: primary
Jovana Markovic Tsougos
Role: primary
Ilias Kosmas, MD
Role: primary
Foteini Ereliadou
Role: primary
Teodora Pantic, MD
Role: primary
Una Radak, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Hamid N, Jorde UP, Reisman M, Latib A, Lim DS, Joseph SM, Kurlianskaya A, Polonetsky O, Neuzil P, Reddy V, Foerst J, Gada H, Grubb KJ, Silva G, Kereiakes D, Shreenivas S, Pinney S, Davidavicius G, Sorajja P, Boehmer JP, Kleber FX, Perier P, VAN Mieghem NM, Dumonteil N, Leon MB, Burkhoff D. Transcatheter Left Ventricular Restoration in Patients With Heart Failure. J Card Fail. 2023 Jul;29(7):1046-1055. doi: 10.1016/j.cardfail.2023.03.003. Epub 2023 Mar 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.